| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Dental Therapy Under General Anesthesia | 2025-07-01 |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Diabetic Supplies | 2025-07-01 |
| UHC Commercial Medical & Drug | Adzynma (ADAMTS13, Recombinant-Krhn) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Amondys 45® (Casimersen) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Entyvio® (Vedolizumab) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Exondys 51® (Eteplirsen) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Gonadotropin Releasing Hormone Analogs – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Korsuva® (Difelikefalin) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Niktimvo™ (Axatilimab-Csfr) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Saphnelo® (Anifrolumab-Fnia) – Commercial Medical Benefit Drug Policy | 2025-07-01 |